Publications
201
Citations
2,296
Est. group size
~20
Recurring co-author estimate
Active years
16
Publishing since 2011
Naresh Bumma's research focuses on multiple myeloma and light chain amyloidosis, two blood cancers involving abnormal plasma cells. Much of the work evaluates new drug combinations and antibody-based treatments (such as daratumumab, linvoseltamab, and other bispecific antibodies) through clinical trials and comparative effectiveness studies, including analyses of treatment safety, quality of life, and outcomes in stem cell transplant candidates.
Publication output has grown substantially over the last decade, rising from single digits in 2018-2019 to a sustained pace of over 20 papers per year since 2020, with a peak in 2024.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- American Society of Hematology (ASH) 2026 Guidelines on Diagnosis of Light Chain Amyloidosis
Blood Advances · 2026
- Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials
Journal of Clinical Oncology · 2026
- Health-related quality of life with linvoseltamab treatment for relapsed/refractory multiple myeloma in LINKER-MM1
Blood Neoplasia · 2026
- Diagnostic Utility of Immunofixation and Free Light Chain Assay in AL Amyloidosis: A Systematic Review and Meta-analysis
Blood Advances · 2026
- Daratumumab-Bortezomib-Cyclophosphamide-Dexamethasone in Newly Diagnosed Amyloidosis: ANDROMEDA Final Survival Analysis
Blood · 2026
- Comparative efficacy of linvoseltamab versus teclistamab in triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM): Updated matching-adjusted indirect comparison (MAIC) with longer follow-up.
Journal of Clinical Oncology · 2026
- A systematic review of indirect treatment comparisons among recently approved chimeric antigen receptor T-cell and bispecific antibody therapies for triple-class exposed relapsed/refractory multiple myeloma
Figshare · 2026
- A systematic review of indirect treatment comparisons among recently approved chimeric antigen receptor T-cell and bispecific antibody therapies for triple-class exposed relapsed/refractory multiple myeloma
Current Medical Research and Opinion · 2026
- A systematic review of indirect treatment comparisons among recently approved chimeric antigen receptor T-cell and bispecific antibody therapies for triple-class exposed relapsed/refractory multiple myeloma
Figshare · 2026
- Linvoseltamab versus elranatamab for triple-class exposed relapsed or refractory multiple myeloma: an indirect treatment comparison
Leukemia & lymphoma/Leukemia and lymphoma · 2026
- Indirect Comparison of Linvoseltamab Versus Teclistamab for the Treatment of Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia · 2025
- Management recommendations for kidney transplantation in patients with plasma cell dyscrasia
Kidney International · 2025
- Comparative Efficacy of linvoseltamab versus Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma: A Matching-Adjusted Indirect Comparison
Clinical Lymphoma Myeloma & Leukemia · 2025
- Linvoseltamab (LINVO) in Frail Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): A Subgroup Analysis of the LINKER-MM1 Study
Clinical Lymphoma Myeloma & Leukemia · 2025
- Indirect comparison of linvoseltamab versus elranatamab for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).
Journal of Clinical Oncology · 2025
- Blood×54
- Clinical Lymphoma Myeloma & Leukemia×25
- Journal of Clinical Oncology×18
- Transplantation and Cellular Therapy×11
- Biology of Blood and Marrow Transplantation×9
- Yvonne A. Efebera
Medicine · The Ohio State University
- Rafat Abonour
Medicine · Indiana University
- Don M. Benson
Medicine · The Ohio State University
- Don Benson
Medicine · The Ohio State University
- Abdullah Khan
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile